Press Releases

PITTSBURGH, May 16, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today published its 2021 Sustainability Report, outlining the company's 2021 achievements and progress across key areas including Access and Global Health, Employees, Environmental Stewardship and Community Engagement and including details on Viatris' continued efforts to support employees and their families while maintaining a stable supply of medicines during the ongoing COVID-19 pandemic.

View PDF

As part of the report, the company committed to initial company-wide and multi-year goals in three key areas – access, the environment and diversity, equity and inclusion (DE&I).  These include providing antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than two million children living with HIV/ AIDS, between 2022 and the end of 2025; impacting 100 million patients via healthcare professional education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025. Viatris has committed to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 and reducing Scope 3 GHG emissions covering purchase goods and services, capital goods, fuel and energy related alternatives and upstream transportation and distribution 25% by 2030. The company has also set goals to enhance DE&I in support of attracting, developing and retaining diverse talent and building a more inclusive environment.

"At Viatris, we believe companies can be a force for good. Our colleagues around the world strive to make a positive difference and during our first full year as Viatris, they truly exemplified the power that lies in collaboration, focus and resilience," said Michael Goettler, CEO for Viatris. "We are proud of the strong foundation we have built, the progress we have made and our commitment to acting responsibly as we support providing sustainable access to medicine for patients around the world, regardless of geography or circumstance, while building a simpler, stronger and more focused company."

Here are some of Viatris' key initiatives, progress and accomplishments in 2021, in collaboration with our partners:

• Approximately 40% of adults and more than 60% of children being treated for HIV used a Viatris product
• More than 80 billion doses of medicine sold across more than 165 countries and territories, reaching approximately 90% of low- and lower-middle-income countries with approximately 7.7 billion doses
• Established a formal program for building DE&I, beginning with understanding the current makeup of our workforce to inform how we will embed DE&I throughout the organization, support representation and enhance the employee experience overall
• Signed on to the UN Global Compact CEO Water Mandate and UN Women's Empowerment Principles
• Approximately 500 million doses of medicines donated across a variety of therapeutic areas by working through a trusted network of partners

"At Viatris, our commitment to access to medicine and supporting resilient healthcare systems by advancing sustainable and responsible operations truly is a collective mission, realized through the dedication of colleagues across the organization," said Lara Ramsburg, Head of Corporate Affairs of Viatris.

Viatris is dedicated to transparent annual reporting on environmental, social and governance matters, continuously working to further enhance its disclosures.

To learn more about how the company partners with stakeholders throughout the globe to address some of the world's most pressing health, environmental and social issues, click here.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube. 

Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements about the company committing to initial company-wide and multi-year goals in three key areas – access, the environment and DE&I; that these include providing antiretroviral (ARV) therapy equivalent to a total of 30 million patients, including more than two million children living with HIV/ AIDS, between 2022 and the end of 2025; impact 100 million patients via healthcare professional education and outreach regarding prevention, diagnosis and treatment options for cardiovascular disease, diabetes, cancer and other important chronic conditions to improve outcomes through the NCD Academy by the end of 2025; that Viatris has committed to reducing absolute Scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 and reducing Scope 3 GHG emissions covering purchase goods and services, capital goods, fuel and energy related alternatives and upstream transportation and distribution 25% by 2031; and that the company has also set goals to enhance DE&I in support of attracting, developing and retaining diverse talent and building a more inclusive environment. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to: the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by the COVID-19 pandemic; the pending transaction between Viatris and Biocon Biologics Limited, pursuant to which Viatris will contribute its biosimilar products and programs to Biocon Biologics in exchange for cash consideration and a convertible preferred equity interest in Biocon Biologics, may not achieve its intended benefits; the integration of Mylan N.V. and Pfizer Inc.'s Upjohn business (the "Upjohn Business"), which combined to form Viatris (the "Combination") and the implementation of our global restructuring initiatives being more difficult, time consuming or costly than expected, or being unsuccessful; the ability to achieve expected benefits, synergies, and operating efficiencies in connection with the Combination or its restructuring initiatives within the expected timeframe or at all; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

SOURCE Viatris Inc.